Aranesp® is a proven option for patients with anemia due to CKD
patients received Aranesp®
during clinical trials1,*
*Cumulative estimate based on
subjects who received ≥ 1 dose (actual
exposure) for completed and ongoing (per protocol randomization)
studies from launch through October 31, 2016.
†US exposure estimate methodology based on total monthly dollar
assumed monthly revenue per patient, assumed patient loss
assumed route of administration share from 2002 through
2017. It assumes an increase on the patient level, not
accounting for dose
increases, and does not reflect price increases
More than 95% of patients
dialysis had their Hb
‡Vanrenterghem et al, Kidney Int. 2002. Data from
a multicenter, randomized, open-label study
comparing epoetin, given 1, 2, or 3 times weekly
IV or SC, with Aranesp®, at a reduced dose
frequency, in dialysis patients (N = 522). Dose
adjustments were made as necessary and per
study protocol to maintain individual patients’ Hb
within a target range of –1.0 to +1.5 g/dL of their
baseline Hb and between 9 g/dL and 13 g/dL for up
to 52 weeks. The primary endpoint was the
change in Hb between baseline and the
evaluation period at weeks 25 to 32 of treatment.
The mean change in Hb from baseline to the
evaluation period was similar in the Aranesp® and
epoetin groups, and the difference between the
two treatment groups was 0.03 g/dL. This was
not a statistically significant or clinically relevant
difference. 97% (178/183) of patients’ Hb levels
were successfully maintained on Aranesp® QW or
less after conversion from epoetin during the
Amgen sales support team
Your sales rep team and key account managers are
your source of
support for any questions about
ordering or details about Aranesp®.
Facility management tools
Obtain tools from your Amgen Sales Support Team to
Coverage and reimbursement support
An Amgen Reimbursement Specialist can assist you
verification, co-pays, and reimbursement resources.
Reliability in supply is essential to Amgen
Since 2001, Amgen has consistently supplied
to support patients.4,§
In the last 10 years, even in the wake of natural
and other disruptive events, customers**
experienced a supply shortage of Aranesp®.4,5
§Based on 99.9% of product shipped to Amgen Authorized Distributors of Record only.
**US wholesalers only (data through April 17, 2017).
Learn more about Amgen manufacturing at
Designed specifically for nephrology healthcare
anemiahub.com is your comprehensive source for anemia
Not an Anemia HubTM member? Register here
For nearly 30 years,
a commitment to the
Important Safety Information
If you decide to take Aranesp®, your healthcare provider should prescribe the smallest dose that is necessary to reduce your chance of needing RBC transfusions.
If your hemoglobin level stays too high or goes up too quickly, this may lead to serious health problems which may result in death. These serious health problems may happen if you take Aranesp®, even if you do not have an increase in your hemoglobin level.
Before taking Aranesp®, tell your doctor if you: have heart disease; have high blood pressure; have had a seizure or stroke; or if you are pregnant or breastfeeding, or plan to become pregnant or breastfeed.
If you know you are allergic to latex, talk to your healthcare provider before using Aranesp® because the needle cover on the prefilled syringe contains latex.
These are not all the possible side effects of Aranesp®. Tell your healthcare provider about any side effects that bother you or do not go away.
You are encouraged to report negative side effects of prescription drugs to the US Food and Drug Administration (FDA). Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Aranesp® is a prescription medicine used to treat a lower than normal number of red blood cells (anemia) caused by chronic kidney disease in patients on dialysis and not on dialysis.
Aranesp® is a prescription medicine used to treat a lower than normal number of red blood cells (anemia) caused by chemotherapy that will be used for at least two months after starting Aranesp®.
Aranesp® has not been proven to improve quality of life, fatigue, or well-being.
Aranesp® should not be used for the treatment of anemia: